F003 Psychocutaneous Disease: Treating the Difficult Patient
DESCRIPTION
Common psychocutaneous diseases include delusional infestation (delusions of parasitosis), skin picking disorder and other body-focused and repetitive behaviors, and body dysmorphic disorder (BDD). Affected individuals routinely refuse a psychiatric referral, so the burden of care often falls exclusively upon the dermatologist. The session will focus on managing such conditions in the complex patient, including using effective drugs and psychotherapies. Speakers will also discuss diagnostic tools for BDD and Zoom dysmorphia, skin conditions with secondary mental illness, and personality disorders in the dermatology setting; lastly, how to handle angry-frustrated and aggressive patients and implement stress reduction interventions.
LEARNING OBJECTIVES
Describe common psychocutaneous diseases and recognize the associated psychiatric/psychosocial comorbidities.
Discuss skin diseases associated with mental illness and the approach to the patient with a personality disorder in the dermatology setting.
Develop appropriate management plans for the difficult patient with a psychocutaneous disease, including effective drugs and psychotherapies. Discuss how to handle angry-frustrated and aggressive patients and implement stress reduction interventions.
SCHEDULE
9:00 AM
A rose by any other name: the approach to the patient with delusional infestation
Jenny Eileen Murase, MD, FAAD
9:15 AM
Skin picking disorder and other body-focused repetitive behaviors: how to help your patients
Katlein Franca, PhD, MD, MSc
9:30 AM
Body dysmorphic disorder and Zoom dysmorphia: red flags and diagnostic tools
George Kroumpouzos, MD, PhD, FAAD
9:45 AM
Psychopharmacology in dermatology
John Y. M. Koo, MD, FAAD
10:00 AM
Q&A
George Kroumpouzos, MD, PhD, FAAD, Katlein Franca, PhD, MD, MSc, John Y. M. Koo, MD, FAAD, Jenny Eileen Murase, MD, FAAD
10:10 AM
Skin conditions with secondary mental illness
Nicholas Brownstone, MD
10:25 AM
Personality disorders and the difficult dermatology patient
Mio Nakamura, MD, MS, FAAD
10:40 AM
How to turn patient conflict into partnership
Jason S. Reichenberg, MD, FAAD
10:55 AM
Q&A
Nicholas Brownstone, MD, Mio Nakamura, MD, MS, FAAD, Jason S. Reichenberg, MD, FAAD
DIRECTOR
George Kroumpouzos, MD, PhD, FAAD
SPEAKERS
Nicholas Brownstone, MD
Katlein Franca, PhD, MD, MSc
John Y. M. Koo, MD, FAAD
Jenny Eileen Murase, MD, FAAD
Mio Nakamura, MD, MS, FAAD
Jason S. Reichenberg, MD, FAAD
HANDOUTS
DISCLOSURES
Nicholas Brownstone, MD
Neutrogena – Speaker(Honoraria); UCB – Speaker(Honoraria);
Katlein Franca, PhD, MD, MSc
Health.com – Advisory Board(Honoraria); Springer Publishing – Other(Other Financial Benefit); Verywell Health – Advisory Board(Fees); Wiley-Blackwell – Other(Other Financial Benefit);
John Y. M. Koo, MD, FAAD
AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); Castle Biosciences – Advisory Board(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Leo Pharma – Advisory Board(Honoraria); Leo Pharma Inc. – Speaker(Honoraria); Pfizer Inc. – Speaker(Fees); Regeneron – Speaker(Honoraria); Sanofi – Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria); UCB – Speaker(Honoraria);
George Kroumpouzos, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Jenny Eileen Murase, MD, FAAD
AbbVie – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); Blueprints Medicine – Speaker(Honoraria); Eli Lilly – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker/Faculty Education(Honoraria); Galderma – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); Leo Pharma Inc – Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Speaker(Honoraria); Phothera – Advisory Board(Honoraria); Regeneron – Speaker/Faculty Education(Honoraria); Sanofi – Speaker(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); UCB – Advisory Board(Honoraria), Consultant(Honoraria), Speaker/Faculty Education(Honoraria); UpToDate – Consultant(Honoraria);
Mio Nakamura, MD, MS, FAAD
Amgen – Investigator(Grants/Research Funding); argenx – Advisory Board(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); janssen – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sol-Gel Technologies – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding);
Jason S. Reichenberg, MD, FAAD
No financial relationships exist with ineligible companies.